Spine PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology byJosh SandbergSeptember 13, 2024
Spine Top Stories Aclarion Provides Corporate Update on Nociscan AI Technology Milestones byJosh SandbergSeptember 12, 2024
Spine Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial byJosh SandbergSeptember 10, 2024
Spine Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan’s AI Generated Biomarker Data Changes Surgical Treatment Plans byJosh SandbergAugust 21, 2024
Financial Hospitals Aclarion Hits Another Key Milestone by Adding Vitality – Third Major Payer to Cover Nociscan in Greater UK byJosh SandbergAugust 13, 2024
Financial Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK byTim AllenJuly 9, 2024
Spine Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London byJosh SandbergJune 25, 2024
Spine Aclarion’s Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain byTim AllenApril 25, 2024
Spine Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs byJosh SandbergMarch 4, 2024
Neuro Spine Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD byJosh SandbergJanuary 22, 2024
